Pivot to Asia: inflammatory bowel disease burden

Prashant Singh; Ashwin Ananthakrishnan; Vineet Ahuja

doi:10.5217/ir.2017.15.1.138

Articles

Page Path: HOME > Intest Res > Volume 15(1); 2017 > Article

Brief Communication Pivot to Asia: inflammatory bowel disease burden: Prashant Singh¹, Ashwin Ananthakrishnan², Vineet Ahuja³; Intestinal Research 2017;15(1):138-141.
DOI: https://doi.org/10.5217/ir.2017.15.1.138
Published online: January 31, 2017

¹Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

²Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.

³Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.

Correspondence to Vineet Ahuja, Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi 110029, India. Tel: +91-11-26588500, Fax: +91-11-26588641, vineet.aiims@gmail.com

• Received: October 21, 2016 • Revised: November 30, 2016 • Accepted: December 2, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

9,861 Views
110 Download
77 Web of Science
81 Crossref
82 Scopus

Full Article

Download PDF

NOTES
REFERENCES

Inflammatory bowel disease (IBD) is a chronic, relapsing, inflammatory disorder of the gastrointestinal tract, and includes UC and CD. IBD results from a combination of genetic susceptibility, environmental exposure, and dysregulated response to intestinal microbiota.1 The incidence and prevalence of IBD has been increasing worldwide and appears to be highest in North America and Europe.1 Despite its previously low incidence, Asia has experienced a significant increase in IBD in the past two decades, while Europe has seen a plateau or even a decreasing incidence.1 The highest incidence of IBD in Asia has been reported from East and South Asian countries of China, Japan, South Korea, and India.1 With the plateau of IBD incidence in several Western countries and rising incidence in Asian countries, the geographic landscape of IBD may be rapidly changing.

In a systematic review on the epidemiology of IBD, Molodecky et al.2 reported the United States and Sweden among the countries with the highest occurrence of IBD. They also reported China, Japan, South Korea, and India among the countries with the lowest occurrence of IBD.2 Despite the data on the prevalence and incidence of UC and CD, the estimated current disease burden of these diseases in various Asian countries in comparison to Western countries is not clear. We aimed to estimate the disease burden of UC and CD in these six countries, with 2010 as the reference year.

We searched PubMed with keywords “Ulcerative colitis,” “Crohn's disease” or “Inflammatory bowel disease,” and “incidence” or “prevalence.” Each was cross-referenced with the six countries mentioned above. The study with the most recent data on prevalence and incidence of CD and/or UC was selected for each country. Wherever possible, a population-based study was selected to estimate both prevalence and incidence. If population-based data were not available, the latest hospital-based study was used. Prevalence and annual incidence was derived from each of the selected studies.3 4 5 6 7 8 9 10 11 12 The census data from each country were used to estimate their national population in the year of the prevalence study. Available data on prevalence was superimposed on the national population at the time of the study to estimate the disease burden of CD or UC.3 4 5 6 7 8 9 10 11 12 Data on incidence rates were used to calculate the new cases of UC or CD since the last prevalence study.7 8 9 12 For most of the selected countries, the rate of increase in annual incidence of UC and/or CD is not known; thus, to maintain uniformity, the incidence was assumed to be stable since last reported. The most current annual incidence rates available were superimposed on the national population at the time of the latest prevalence study to calculate the number of patients newly diagnosed with UC or CD every year.3 4 5 6 7 8 9 10 11 12 This was then multiplied by the number of years between the last prevalence study and 2010 to calculate the newly diagnosed cases of CD or UC between the last prevalence calculation and 2010. The total national disease burden of UC and CD in 2010 was calculated by adding this number of newly diagnosed cases of CD or UC to the baseline national disease burden at the time of the latest prevalence study.

The estimated disease burden in 2010 for India was 1.1 million patients with UC, as compared to 0.8 million in the United States and 0.5 million in China. The estimated burden of UC patients in the other above mentioned countries is detailed in Table 1.

In 2010, the estimated number of patients with CD in the United States was about 0.8 million. This is much higher compared to the CD burden in China (0.09 million), Japan (0.03 million), Sweden (0.02 million), and South Korea (0.01 million). There are no prevalence and/or incidence studies on CD in India, but hospital-based studies have shown that for every four cases of UC, at least one CD case is detected in India.13 14 Thus, the presumed burden of CD in India in 2010 was about 0.3 million.

Among the six countries studied, the United States appears to have the highest burden of IBD patients (1.6 million), closely followed by 1.4 million in India. The disease burden of other countries is summarized in Table 1.

Our analysis shows that despite being considered countries with low occurrence of UC and CD, many Asian countries have substantially higher numbers of IBD patients compared to Western countries considered to have high occurrence of IBD. The prevalence of UC in India (44.3 per 100,000) is much lower than that in the United States (286.3 per 100,000) or Sweden (350 per 100,000).5 6 7 Moreover, the incidence of UC in India (6.02 per 100,000) is much lower than the UC incidence in United States (8.8 per 100,000) and Sweden (20 per 100,000).7 15 16 However, because of its population size, India has a much higher disease burden of UC compared to other countries with much higher incidence and prevalence of UC, including the United States and Sweden. The disease burden of CD appears to be highest in the United States, with about 0.8 million CD patients. We estimate that there are about 0.3 million CD patients in India. Interestingly, despite much lower CD incidence and prevalence compared to Sweden, China, and Japan have a burden of CD almost 4.5 times and 3 times higher, respectively.

Thus, India has the highest burden of IBD in Asia and one of the highest in the world. Despite the low prevalence and incidence of IBD, Asian countries might have a significantly higher burden of IBD patients compared to Western countries. While the incidence and prevalence of IBD have stabilized in North America and Europe, both continue to rise in low-incidence regions such as Eastern Europe, Africa, and Eastern and Southern Asia.1 16 This changing epidemiology of IBD over time and geography suggests that environmental factors play a major role in pathogenesis. Changes in lifestyle in developing countries have resulted in more “Westernized” diets, leading to higher consumption of fatty acids, refined sugars, and fast food and less consumption of fruits, vegetables, and fiber.17 18 19 Urbanization of societies leading to improved hygiene status, change in microbial exposure, and antibiotic use could also be contributing to the pathogenesis.1 17 18 In addition, the susceptibility genes for IBD appear to be different among Western and Asian countries.18 This rising incidence of IBD in developing countries gives us a novel chance to explore the genetic and environmental factors underlying the pathogenesis of IBD.

Increasing disease burden of IBD among developing countries raises several concerns. First, it is unclear whether healthcare systems in these countries are prepared to deal with the burden. Clearly, the disease burden of IBD in several Asian countries is much higher than we expected, and in many of these regions, IBD is still considered rare, leading to frequent underdiagnosis or misdiagnosis.1 17 18 Epidemiological studies from the majority of developing countries are lacking, making it difficult to estimate the exact burden of UC and/or CD in several Asian countries. Well-designed pannational epidemiological studies covering both rural and urban settings, along with regions with varied ethnicities, are much needed. There is also a need to increase awareness among healthcare providers on the appropriate diagnosis of IBD in countries with high background prevalence of infections, especially tuberculosis. Use of biologics in developing countries is limited due to high cost and high prevalence of infections such as tuberculosis.18 The major significance of the awareness of the high disease burden of IBD in India is that it outlines the urgent necessity for an adequate number of health care providers, facilities for diagnosis and treatment of a massive patient load, and sensitization of health care agencies to promote research on cost-effective methods of therapy. Despite one of the highest disease burdens of IBD in the world, India has one of the most deficient public health insurance systems in Asia.19 As most Indian patients end up paying for their medical expense, only a minority of patients who need expensive therapies such as biologics can afford them.19

Our study also had several limitations. First, the disease burden in our study is only a close estimation of the exact number, as we have used prevalence and incidence rates in our calculation that are based on studies limited to a particular geographic region, and are not pan-national. Second, we used the last available incidence rates for our calculation, which might have led to underestimation of the disease burden, given the fact that available studies suggest rising incidence of IBD in some Asian countries. However, recent studies from South Korea suggest that the incidence might also be plateauing in other Asian countries.1 In addition, several prevalence and incidence values have been estimated from hospital-based studies. For example, there are no population-based prevalence studies on UC from China; thus, we used the hospital-based study by Chow et al.8 In addition, the number of new cases diagnosed since the last prevalence study was calculated used the baseline population at the time of prevalence calculation, and did not take into account population growth since then. Thus, the disease burden estimation in countries such as India, where the population is growing rapidly, is likely an underestimation.

In conclusion, the disease burden of IBD in developing countries is much higher than in the developed world. It is imperative that their healthcare systems be prepared for this challenge.

NOTES

Financial support: None.

Conflict of interest: None.

REFERENCES

1. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016;14:111–119.PMID: 27175111.Article PubMed PMC
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.e42.PMID: 22001864.Article PubMed
3. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542–549.PMID: 17941073.Article PubMed
4. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn's disease in Japan. J Gastroenterol 2009;44:659–665.PMID: 19424654.Article PubMed
5. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther 2014;39:57–68.PMID: 24127738.Article PubMed
6. Shivashankar R, Tremaine WJ, Harmsen WS, Zinsmeister A, Loftus E. Updated incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota (1970-2010). Am J Gastroenterol 2014;109(Suppl 2): S449.Article
7. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, north India. Gut 2003;52:1587–1590.PMID: 14570727.Article PubMed PMC
8. Chow DK, Leong RW, Tsoi KK, et al. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol 2009;104:647–654.PMID: 19262521.Article PubMed PDF
9. Morita N, Toki S, Hirohashi T, et al. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J Gastroenterol 1995;30(Suppl 8): 1–4.Article
10. Lok KH, Hung HG, Ng CH, Li KK, Li KF, Szeto ML. The epidemiology and clinical characteristics of Crohn's disease in the Hong Kong Chinese population: experiences from a regional hospital. Hong Kong Med J 2007;13:436–441.PMID: 18057431.PubMed
11. Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000;43(10 Suppl): S85–S93.PMID: 11052483.Article PubMed
12. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol 2013;28:1148–1153.PMID: 23432198.Article PubMed
13. Ramakrishna BS, Makharia GK, Ahuja V, et al. Indian Society of Gastroenterology consensus statements on Crohn's disease in India. Indian J Gastroenterol 2015;34:3–22.PMID: 25772856.Article PubMed
14. Ahuja V, Tandon RK. Inflammatory bowel disease: the Indian augury. Indian J Gastroenterol 2012;31:294–296.PMID: 23150035.Article PubMed
15. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13:254–261.PMID: 17206702.Article PubMed
16. Sjöberg D, Holmström T, Larsson M, et al. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005-2009: results from the IBD cohort of the Uppsala Region (ICURE). J Crohns Colitis 2013;7:e351–e357.PMID: 23491313.Article PubMed PDF
17. Ng SC. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol 2014;28:363–372.PMID: 24913377.Article PubMed
18. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012;27:1266–1280.PMID: 22497584.Article PubMed
19. Wei SC. Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries. Intest Res 2016;14:218–223.PMID: 27433143.Article PubMed PMC

Table 1

Absolute Number of IBD Cases in Various Regions of the World (Calculated for 2010)

Country	Year	Population at the time of prevalence study	UC prevalence^a	UC incidence^a	UC disease burden in 2010	CD prevalence^a	CD incidence^a	CD disease burden in 2010	IBD disease burden in 2010
South Korea	2005	47,278,951	30.873	3.083	21,875.97	11.243	1.343	8,481.80	30,357.77
Japan	2005	127,768,000	63.604	1.959	93,717.83	21.204	1.2011	34,752.90	128,471.90
Sweden	2010	9,415,570	3505	N/A	32,835.00	1905	N/A	18,299.00	51,143.90
USA	2010	308,745,538	286.36	N/A	883,938.48	246.76	N/A	761,675.24	1,645,621.62
India	1999	1,016,118,000	44.37	6.027	1,123,013.61	-	-	280,753.00	1,403,766.61
China	2006	1,311,400,000	26.58	2.058	455,055.80	2.710	1.0912	92,584.84	547,641.73

^aNumber of patients per 100,000 people.

N/A, as the prevalence study is from 2010, incidence data are not needed to estimate disease burden.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening
Suprabhat Giri, Sukanya Bhrugumalla, Akash Shukla, Sagar Gangadhar, Srujan Reddy, Sumaswi Angadi, Leela Shinde, Aditya Kale
Arab Journal of Gastroenterology.2025; 26(1): 33. CrossRef
Evaluation of the mechanism of action of Aegle marmelos in a murine model of 3% dextran sulphate sodium induced acute colitis
Alok Nachane, Sandhya K. Kamat, Manoj Radhakrishnan, Gita Nataraj, Sunil S. Kuyare
International Journal of Basic & Clinical Pharmacology.2025; 14(2): 275. CrossRef
A Spermidine Derivative Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice by Inhibiting the MAPK4/AKT Signaling Pathway
Yuxin Zhang, Zeyuan Deng, Hongyan Li, Zeyin Jiang
Foods.2025; 14(7): 1110. CrossRef
FoxP3-positive T regulatory cells and its effector mechanisms in Crohn’s disease: an immunohistochemical and image morphometric analysis on endoscopic mucosal biopsies
Susama Patra, Shalini Chaudhary, Subash Chandra Samal, Pavithra Ayyanar, Somanath Padhi, Hemanta Kumar Nayak, Amit Kumar Satapathy, Saurav Nayak, Ajit Sahu, Tapaskanti Parida, Mohammed Shahin
European Journal of Gastroenterology & Hepatology.2025; 37(7): 799. CrossRef
Study on the ameliorative effect of marine fungus Hansfordia sinuosae extracellular polysaccharide on DSS-induced ulcerative colitis and depression-like behavior
Wei Wang, Huiru Li, Dezhao Yang, Wanshuang Cai, Hongxia Che, Hongyan Li
International Journal of Biological Macromolecules.2025; 309: 142852. CrossRef
Developing IBD counsellors in low- and middle-income countries: bridging gaps in patient care
Arshdeep Singh, Arshia Bhardwaj, Riya Sharma, Vandana Midha, Ajit Sood
eClinicalMedicine.2025; 83: 103218. CrossRef
Urinary lipoarabinomannan: A novel diagnostic tool for distinguishing gastrointestinal tuberculosis from Crohn’s disease
Mukesh Singh, Manjeet Kumar Goyal, Himanshu Narang, Malambo Mubbunu, Peeyush Kumar, Bhaskar Kante, Sudheer K. Vuyyuru, Ashish Dutt Upadhyay, Prasenjit Das, Ankur Goyal, Raju Sharma, Urvashi B. Singh, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2025;[Epub] CrossRef
IBD Card: Promoting continuity in care for patients with inflammatory bowel disease
Harshavardhan Telaprolu, Anupam K. Singh, Vishal Sharma, Usha Dutta
Indian Journal of Gastroenterology.2024; 43(1): 7. CrossRef
Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
Mukesh Kumar Ranjan, Peeyush Kumar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Sandeep K Mundhra, Rithvik Golla, Shubi Virmani, Raju Sharma, Peush Sahni, Prasenjit Das, Mani Kalaivani, Ashish Datt Upadhyay, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Journal of Crohn's and Colitis.2024; 18(2): 192. CrossRef
Perianal fistulizing Crohn’s disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies
Jalpa Devi, David H. Ballard, Tina Aswani-Omprakash, Alyssa M. Parian, Parakkal Deepak
Indian Journal of Gastroenterology.2024; 43(1): 48. CrossRef
Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB
Renata de Sá Brito Fróes, Adriana Ribas Andrade, Mikaell Alexandre Gouvea Faria, Heitor Siffert Pereira de Souza, Rogério Serafim Parra, Cyrla Zaltman, Carlos Henrique Marques dos Santos, Mauro Bafutto, Abel Botelho Quaresma, Genoile Oliveira Santana, Raf
Scientific Reports.2024;[Epub] CrossRef
Challenges in IBD Research 2024: Environmental Triggers
Ashwin N Ananthakrishnan, Kostantinos Gerasimidis, Shuk-Mei Ho, Emeran Mayer, Jennifer Pollock, Shefali Soni, Gary D Wu, Jalil Benyacoub, Basmah Ali, Alex Favreau, Denise Elsbree Smith, Ji-eun Oh, Caren Heller, Andres Hurtado-Lorenzo, Alan Moss, Ken Croit
Inflammatory Bowel Diseases.2024; 30(Supplement): S19. CrossRef
Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatment
Aaron T. Kao, Christian V. Cabanlong, Kendra Padilla, Xiang Xue
Acta Pharmaceutica Sinica B.2024; 14(9): 3785. CrossRef
Analysis of the effect of hypusination in myeloid cells on colitis and colitis-associated cancer.
Alain P. Gobert, Jordan Finley, Mohammad Asim, Daniel P. Barry, Margaret M. Allaman, Caroline V. Hawkins, Kamery J. Williams, Alberto G. Delagado, Raghavendra G. Mirmira, Shilin Zhao, M. Blanca Piazuelo, M. Kay Washington, Lori A. Coburn, Keith T. Wilson
Heliyon.2024; : e33838. CrossRef
Debate on the relationship between Helicobacter pylori infection and inflammatory bowel disease: a bibliometric analysis
Ziye Wang, Shiqing Zhao, Xiaotian Zhong, Yi Su, Yahan Song, Jun Li, Yanyan Shi
Frontiers in Microbiology.2024;[Epub] CrossRef
Ileocolic Enteroenteric Fistula in Small Bowel Obstruction With Cecum Perforation in the Pediatric Age Group: A Case Report of a Rare Complication
Survesh k Gupta, Umesh K Gupta, Rafey A Rahman, Anil Kumar
Cureus.2024;[Epub] CrossRef
Granulomatous inflammation is less common in delayed-onset Crohn's disease
Madeline Vithya Barnaba Durairaj, Rajeeb Jaleel, Anna B Pulimood
Tropical Doctor.2023; 53(1): 113. CrossRef
High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India
Bhaskar Kante, Sudheer Kumar Vuyyuru, Ritu Gupta, Tanima Dwivedi, Peeyush Kumar, Sandeep Mundhra, Rithvik Golla, Shubi Virmani, Mahak Verma, Govind Makharia, Vineet Ahuja, Saurabh Kedia
Indian Journal of Gastroenterology.2023; 42(1): 70. CrossRef
Interferon-gamma release assay has poor diagnostic accuracy in differentiating intestinal tuberculosis from Crohn’s disease in tuberculosis endemic areas
Karan Sachdeva, Peeyush Kumar, Bhaskar Kante, Sudheer K. Vuyyuru, Srikant Mohta, Mukesh K. Ranjan, Mukesh K. Singh, Mahak Verma, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Intestinal Research.2023; 21(2): 226. CrossRef
Hypusination Maintains Intestinal Homeostasis and Prevents Colitis and Carcinogenesis by Enhancing Aldehyde Detoxification
Alain P. Gobert, Thaddeus M. Smith, Yvonne L. Latour, Mohammad Asim, Daniel P. Barry, Margaret M. Allaman, Kamery J. Williams, Kara M. McNamara, Alberto G. Delgado, Sarah P. Short, Raghavendra G. Mirmira, Kristie L. Rose, Kevin L. Schey, Irene Zagol-Ikapi
Gastroenterology.2023; 165(3): 656. CrossRef
Differentiating gastrointestinal tuberculosis and Crohn's disease- a comprehensive review
Arup Choudhury, Jasdeep Dhillon, Aravind Sekar, Pankaj Gupta, Harjeet Singh, Vishal Sharma
BMC Gastroenterology.2023;[Epub] CrossRef
Colon-Adhering Delivery System with Inflammation Responsiveness for Localized Therapy of Experimental Colitis
Ajay Kumar, Kanika, Vibhu Kumar, Anas Ahmad, Rakesh Kumar Mishra, Ahmed Nadeem, Nahid Siddiqui, Md Meraj Ansari, Syed Shadab Raza, Kanthi Kiran Kondepudi, Rehan Khan
ACS Biomaterials Science & Engineering.2023; 9(8): 4781. CrossRef
Diagnosis of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Han Hee Lee, Jae Jun Park, Bo-In Lee, Ida Hilmi, Jose Sollano, Zhi Hua Ran
Intestinal Research.2023; 21(3): 328. CrossRef
Synthesis of some Curcumin derivatives of Non-Steroidal Anti-Inflammatory (NSAIDs) Prodrugs for Treatment of Inflammatory Bowel Diseases
Yogendra Kumar, Nidhi Agrawal, Meenakshi Jaiswal
Research Journal of Pharmacy and Technology.2023; : 2733. CrossRef
Inflammatory Bowel Disease and X (Formerly Twitter) Influencers: Who Are They and What Do They Say?
Ayushi Garg, Aalam Sohal, Shivam Kalra, Carol Singh, Ishandeep Singh, Jasneet Grewal, Rohin Kansal, Kashish Malhotra, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Ajit Sood, Ashvind Bawa
Cureus.2023;[Epub] CrossRef
Protective Role of Spermidine in Colitis and Colon Carcinogenesis
Alain P. Gobert, Yvonne L. Latour, Mohammad Asim, Daniel P. Barry, Margaret M. Allaman, Jordan L. Finley, Thaddeus M. Smith, Kara M. McNamara, Kshipra Singh, Johanna C. Sierra, Alberto G. Delgado, Paula B. Luis, Claus Schneider, M. Kay Washington, M. Blan
Gastroenterology.2022; 162(3): 813. CrossRef
Geosocial Features and Loss of Biodiversity Underlie Variable Rates of Inflammatory Bowel Disease in a Large Developing Country: A Population-Based Study
Andre da Luz Moreira, Luiz Felipe de Campos Lobato, Jessica Pronestino de Lima Moreira, Ronir Raggio Luiz, Celeste Elia, Claudio Fiocchi, Heitor Siffert Pereira de Souza
Inflammatory Bowel Diseases.2022; 28(11): 1696. CrossRef
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit
Alimentary Pharmacology & Therapeutics.2022; 55(11): 1431. CrossRef
Differential colitis susceptibility of Th1- and Th2-biased mice: A multi-omics approach
Sohini Mukhopadhyay, Subha Saha, Subhayan Chakraborty, Punit Prasad, Arindam Ghosh, Palok Aich, Lili Chen
PLOS ONE.2022; 17(3): e0264400. CrossRef
Genome-wide DNA methylation profiling in differentiating Crohn’s disease from intestinal tuberculosis
Hao Wu, Hongchun Liu, Haining Liu, Yanjie Chen, Taotao Liu, Xizhong Shen, Lili Liu
Genes & Genomics.2022; 44(5): 603. CrossRef
Addition of computed tomography chest increases the diagnosis rate in patients with suspected intestinal tuberculosis
Saurabh Kedia, Raju Sharma, Sudheer Kumar Vuyyuru, Deepak Madhu, Pabitra Sahu, Bhaskar Kante, Prasenjit Das, Ankur Goyal, Karan Madan, Govind Makharia, Vineet Ahuja
Intestinal Research.2022; 20(2): 184. CrossRef
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intestinal Research.2022; 20(2): 159. CrossRef
Minimal risk of lymphoma and non‐melanoma skin cancer despite long‐term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India
Mukesh Kumar Ranjan, Bhaskar Kante, Sudheer Kumar Vuyyuru, Peeyush Kumar, Sandeep K Mundhra, Rithvik Golla, Raju Sharma, Peush Sahni, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Journal of Gastroenterology and Hepatology.2022; 37(8): 1544. CrossRef
Does the road to primary prevention of inflammatory bowel disease start from childhood?
Saurabh Kedia, Vineet Ahuja
JGH Open.2022; 6(6): 365. CrossRef
Applying logistic LASSO regression for the diagnosis of atypical Crohn's disease
Ying Li, Fanggen Lu, Yani Yin
Scientific Reports.2022;[Epub] CrossRef
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial
Saurabh Kedia, Shubi Virmani, Sudheer K Vuyyuru, Peeyush Kumar, Bhaskar Kante, Pabitra Sahu, Kanav Kaushal, Mariyam Farooqui, Mukesh Singh, Mahak Verma, Aditya Bajaj, Manasvini Markandey, Karan Sachdeva, Prasenjit Das, Govind K Makharia, Vineet Ahuja
Gut.2022; 71(12): 2401. CrossRef
Thromboembolism is associated with poor prognosis and high mortality in patients with inflammatory bowel disease: A case–control study
Yadukrishna S., Saurabh Kedia, Varun Teja, Sudheer Kumar Vuyyuru, Nidhi Yadav, Pabitra Sahu, Saransh Jain, Dawesh P. Yadav, Sawan Bopanna, Venigalla Pratap Mouli, Deepak Madhu, Raju Sharma, Prasenjit Das, Govind Makharia, Vineet Ahuja
Indian Journal of Gastroenterology.2022;[Epub] CrossRef
INCIDENCE OF INFLAMMATORY BOWEL DISEASE: A SINGLE CENTRE RETROSPECTIVE STUDY
Ajay Kumar OLI, Rohit N MAIDUR, Preetham S HURKADLI, Anita P JAVALGI, Palaksha Kanive JAVAREGOWDA, Mallikarjun GONI
Arquivos de Gastroenterologia.2022; 59(3): 345. CrossRef
Development and Validation of a Smartphone Application for Telenutrition in Patients with Inflammatory Bowel Disease
Arti Gupta, Namrata Singh, Divya Madan, Mariyam Farooqui, Neha Singh, David Mathew Thomas, Bhaskar Kante, Mukesh Singh, Shubi Virmani, Mehak Verma, Aditya Bajaj, Manasvini Markandey, Peeyush Kumar, Sudheer Kumar Vuyyuru, Pabitra Sahu, Nitika Monga, Govind
Diagnostics.2022; 12(10): 2482. CrossRef
Protective Effect of Perilla Oil Against Dextran Sodium Sulfate-Induced Colitis in Mice Challenged with a High-Fat Diet
Shalom Sara Thomas, Youn-Soo Cha, Kyung-Ah Kim
Journal of Medicinal Food.2022; 25(11): 1021. CrossRef
Difficulties in differential diagnosis tuberculosis and Crohn's disease. Case report
Oleg V. Knyazev, Anna V. Kagramanova, Nina A. Fadeeva, Irina G. Pelipas, Albina A. Lishchinskaya, Maria Iu. Zvyaglova, Asfold I. Parfenov
Consilium Medicum.2022; 24(5): 287. CrossRef
Development and Validation of a Digital Health Platform (IBD NutriCare) for Telenutrition in Patients With Inflammatory Bowel Disease
Arti Gupta, Namrata Singh, Bhaskar Kante, Divya Madan, Mariyam Farooqui, Neha Singh, Mukesh Singh, Shubi Virmani, Mehak Verma, Aditya Bajaj, Manasvini Markandey, Peeyush Kumar, Sudheer Kumar Vuyyuru, Pabitra Sahu, Govind Makharia, Saurabh Kedia, Vineet Ah
SSRN Electronic Journal .2022;[Epub] CrossRef
Inflammatory bowel disease in India: challenges and opportunities
Alice Snell, Jonathan Segal, Jimmy Limdi, Rupa Banerjee
Frontline Gastroenterology.2021; 12(5): 390. CrossRef
Incidence and Prevalence of Inflammatory Bowel Disease across Asia
Jihye Park, Jae Hee Cheon
Yonsei Medical Journal.2021; 62(2): 99. CrossRef
The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
Intestinal Research.2021; 19(1): 62. CrossRef
Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn’s disease
Gurasis Boparai, Saurabh Kedia, Devasenathipathy Kandasamy, Raju Sharma, Kumble Seetharama Madhusudhan, Nihar Ranjan Dash, Pabitra Sahu, Sujoy Pal, Peush Sahni, Rajesh Panwar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Davesh P. Yadav, Venigalla Pratap Mouli,
European Journal of Clinical Nutrition.2021; 75(10): 1491. CrossRef
Intestinal tuberculosis or Crohn's disease: Illusion or delusion or allusion
Saurabh Kedia, Vineet Ahuja
JGH Open.2021; 5(2): 177. CrossRef
Deep‐learning system for real‐time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis
Jung Min Kim, Jun Gu Kang, Sungwon Kim, Jae Hee Cheon
Journal of Gastroenterology and Hepatology.2021; 36(8): 2141. CrossRef
Increased Interleukin-10 Expression by the Inhibition of Ca2+-Activated K+ Channel KCa3.1 in CD4+CD25+ Regulatory T Cells in the Recovery Phase in an Inflammatory Bowel Disease Mouse Model
Susumu Ohya, Miki Matsui, Junko Kajikuri, Kyoko Endo, Hiroaki Kito
The Journal of Pharmacology and Experimental Therapeutics.2021; 377(1): 75. CrossRef
The Impact of Migration on the Gut Metagenome of South Asian Canadians
Julia K. Copeland, Gary Chao, Shelley Vanderhout, Erica Acton, Pauline W. Wang, Eric I. Benchimol, Ahmed El-Sohemy, Ken Croitoru, Jennifer L. Gommerman, David S. Guttman
Gut Microbes.2021;[Epub] CrossRef
Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
Ajit Sood, Kirandeep Kaur, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Sarit Sharma, Amarender Singh Puri, Bhabhadev Goswami, Devendra Desai, C. Ganesh Pai, Kiran Peddi, Mathew Philip, Rakesh Kochhar, Sandeep Nijhawan, Shobna Bhatia, N. Sridhara Rao
Intestinal Research.2021; 19(2): 206. CrossRef
Prospective validation of CD4+CD25+FOXP3+ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease
Ritika Rampal, Saurabh Kedia, Mohamad Nahidul Wari, Deepak Madhu, Amit Kumar Singh, Veena Tiwari, V. Pratap Mouli, Srikant Mohta, Govind Makharia, Vineet Ahuja
Intestinal Research.2021; 19(2): 232. CrossRef
A report of nonexistence of the non-Helicobacter pylori Helicobacter species in Iranian patients suffering from inflammatory bowel disease
Samira Pirmanesh, Nasrin Mirzaei, Masoumeh Azimirad, Abbas Yadegar, John Y. Kao, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali
Folia Microbiologica.2021; 66(5): 751. CrossRef
Inflammatory bowel diseases in Tamil Nadu: A survey of demographics, clinical profile, and practices
Rohan V Yewale, Kartik Natarajan, Jeyaraj Ubal Dhus, Sarojini Ashok Parameswaran, Kallipatti Ramaswamy Palaniswamy, Doraisamy Babu Vinish, Aravindh Somasundaram, Arulraj Ramakrishnan, Sibithooran Karmegam, Ramaswamy Saraswathy Arun, Ujjani Shankaraiah Man
JGH Open.2021; 5(11): 1306. CrossRef
Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study
Jooyoung Lee, Jong Pil Im, Kyungdo Han, Jihye Kim, Hyun Jung Lee, Jaeyoung Chun, Joo Sung Kim
Gut and Liver.2020; 14(1): 89. CrossRef
Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century
Ashwin N. Ananthakrishnan, Gilaad G. Kaplan, Siew C. Ng
Clinical Gastroenterology and Hepatology.2020; 18(6): 1252. CrossRef
Inflammatory Bowel Diseases in South Asian Patients: Underappreciated and Understudied
Bharati Kochar
Inflammatory Bowel Diseases.2020;[Epub] CrossRef
Dairy Propionibacterium freudenreichii ameliorates acute colitis by stimulating MUC2 expression in intestinal goblet cell in a DSS-induced colitis rat model
Seongho Ma, Jiah Yeom, Young-Hee Lim
Scientific Reports.2020;[Epub] CrossRef
Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India
Pabitra Sahu, Sudheer K. Vuyyuru, Bhaskar Kante, Ashish Agarwal, Raju Sharma, Prasenjit Das, Rajesh Panwar, Saransh Jain, Sawan Bopanna, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2020; 39(4): 388. CrossRef
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kir
Intestinal Research.2020; 18(4): 355. CrossRef
Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis
Murtaza M. Tambuwala, Mohammed N. Khan, Paul Thompson, Paul A. McCarron
Drug Delivery and Translational Research.2019; 9(1): 14. CrossRef
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
Nagesh Kamat, Saurabh Kedia, Uday C. Ghoshal, Abhimanyu Nehra, Govind Makharia, Ajit Sood, Vandana Midha, Varun Gupta, Gourdas Choudhuri, Vineet Ahuja
Indian Journal of Gastroenterology.2019; 38(1): 44. CrossRef
Differentiating Crohn’s disease from intestinal tuberculosis
Saurabh Kedia, Prasenjit Das, Kumble Seetharama Madhusudhan, Siddhartha Dattagupta, Raju Sharma, Peush Sahni, Govind Makharia, Vineet Ahuja
World Journal of Gastroenterology.2019; 25(4): 418. CrossRef
Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease
Sanjeevani K Tomar, Saurabh Kedia, Namrata Singh, Ashish D Upadhyay, Nagesh Kamat, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja
JGH Open.2019; 3(4): 302. CrossRef
Dietary Arginine Regulates Severity of Experimental Colitis and Affects the Colonic Microbiome
Kshipra Singh, Alain P. Gobert, Lori A. Coburn, Daniel P. Barry, Margaret Allaman, Mohammad Asim, Paula B. Luis, Claus Schneider, Ginger L. Milne, Helen H. Boone, Meghan H. Shilts, M. Kay Washington, Suman R. Das, M. Blanca Piazuelo, Keith T. Wilson
Frontiers in Cellular and Infection Microbiology.2019;[Epub] CrossRef
Impaired neurocognitive and psychomotor performance in patients with inflammatory bowel disease
Ivana Tadin Hadjina, Piero Marin Zivkovic, Andrija Matetic, Doris Rusic, Marino Vilovic, Diana Bajo, Zeljko Puljiz, Ante Tonkic, Josko Bozic
Scientific Reports.2019;[Epub] CrossRef
All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance
Grace B. Hatton, Christine M. Madla, Sarit C. Rabbie, Abdul W. Basit
International Journal of Pharmaceutics.2018; 548(1): 408. CrossRef
Colonic Crohn’s Disease Is Associated with Less Aggressive Disease Course Than Ileal or Ileocolonic Disease
Umang Arora, Saurabh Kedia, Prerna Garg, Sawan Bopanna, Saransh Jain, Dawesh P. Yadav, Sandeep Goyal, Vipin Gupta, Peush Sahni, Sujoy Pal, Nihar Ranjan Dash, Kumble Seetharama Madhusudhan, Raju Sharma, Govind Makharia, Vineet Ahuja
Digestive Diseases and Sciences.2018; 63(6): 1592. CrossRef
Distinct Immunomodulatory Effects of Spermine Oxidase in Colitis Induced by Epithelial Injury or Infection
Alain P. Gobert, Nicole T. Al-Greene, Kshipra Singh, Lori A. Coburn, Johanna C. Sierra, Thomas G. Verriere, Paula B. Luis, Claus Schneider, Mohammad Asim, Margaret M. Allaman, Daniel P. Barry, John L. Cleveland, Christina E. Destefano Shields, Robert A. C
Frontiers in Immunology.2018;[Epub] CrossRef
Combination of increased visceral fat and long segment involvement: Development and validation of an updated imaging marker for differentiating Crohn's disease from intestinal tuberculosis
Saurabh Kedia, Kumble S Madhusudhan, Raju Sharma, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Prasenjit Das, Siddhartha Dattagupta, Govind Makharia, Vineet Ahuja
Journal of Gastroenterology and Hepatology.2018; 33(6): 1234. CrossRef
Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef
Is the emergence of inflammatory bowel disease a prime example of “the third epidemiological transition”?
Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2018; 37(3): 183. CrossRef
The importance of immunization in immune-mediated inflammatory disease cannot be overstated
Sang Hyoung Park
Intestinal Research.2018; 16(3): 325. CrossRef
Management of inflammatory bowel disease in older persons: evolving paradigms
Saurabh Kedia, Jimmy K. Limdi, Vineet Ahuja
Intestinal Research.2018; 16(2): 194. CrossRef
Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study
Saransh Jain, Saurabh Kedia, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Peush Sahni, Sujoy Pal, Nihar Ranjan Dash, Govind Makharia, Simon P. L. Travis, Vineet Ahuja
Intestinal Research.2018; 16(1): 69. CrossRef
Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
Current Infectious Disease Reports.2018;[Epub] CrossRef
High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
Intestinal Research.2018; 16(4): 588. CrossRef
Genetics of ulcerative colitis: putting into perspective the incremental gains from Indian studies
Garima Juyal, Ajit Sood, Vandana Midha, B. K. Thelma
Journal of Genetics.2018; 97(5): 1493. CrossRef
Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014: A Nationwide Population-Based Study
Yoon Suk Jung, Minkyung Han, Won Ho Kim, Sohee Park, Jae Hee Cheon
Digestive Diseases and Sciences.2017; 62(8): 2102. CrossRef
Body Composition in Crohn’s Disease and Ulcerative Colitis: Correlation with Disease Severity and Duration
Dawesh P. Yadav, Saurabh Kedia, Kumble Seetharama Madhusudhan, Sawan Bopanna, Sandeep Goyal, Saransh Jain, Naval K. Vikram, Raju Sharma, Govind K. Makharia, Vineet Ahuja
Canadian Journal of Gastroenterology and Hepatology.2017; 2017: 1. CrossRef
Impact of dietary beliefs and practices on patients with inflammatory bowel disease: An observational study from India
Sanjeevani K Tomar, Saurabh Kedia, Ashish D Upadhyay, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja, Namrata Singh
JGH Open.2017; 1(1): 15. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Pivot to Asia: inflammatory bowel disease burden

Intest Res. 2017;15(1):138-141. Published online January 31, 2017

DOI: https://doi.org/10.5217/ir.2017.15.1.138

XML Download

Related articles

Pivot to Asia: inflammatory bowel disease burden

Table 1

Absolute Number of IBD Cases in Various Regions of the World (Calculated for 2010)

Country	Year	Population at the time of prevalence study	UC prevalence^a	UC incidence^a	UC disease burden in 2010	CD prevalence^a	CD incidence^a	CD disease burden in 2010	IBD disease burden in 2010
South Korea	2005	47,278,951	30.873	3.083	21,875.97	11.243	1.343	8,481.80	30,357.77
Japan	2005	127,768,000	63.604	1.959	93,717.83	21.204	1.2011	34,752.90	128,471.90
Sweden	2010	9,415,570	3505	N/A	32,835.00	1905	N/A	18,299.00	51,143.90
USA	2010	308,745,538	286.36	N/A	883,938.48	246.76	N/A	761,675.24	1,645,621.62
India	1999	1,016,118,000	44.37	6.027	1,123,013.61	-	-	280,753.00	1,403,766.61
China	2006	1,311,400,000	26.58	2.058	455,055.80	2.710	1.0912	92,584.84	547,641.73

^aNumber of patients per 100,000 people.

N/A, as the prevalence study is from 2010, incidence data are not needed to estimate disease burden.

Table 1 Absolute Number of IBD Cases in Various Regions of the World (Calculated for 2010)

^aNumber of patients per 100,000 people.

N/A, as the prevalence study is from 2010, incidence data are not needed to estimate disease burden.